# Sulforaphane Blood Glucose Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/sulforaphane-blood-glucose-randomized-trial-evidence-review
Category: evidence-review
Summary: Sulforaphane Blood Glucose Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass
Last reviewed: 2026-07-09
Reviewed by: Migaku Evidence Review
# Sulforaphane Blood Glucose Randomized Trial: What the Evidence Says

## Quick Answer

Sulforaphane Blood Glucose Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 randomized trial.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials | systematic review | 1 | 2025-11-03 | 10.1186/s12888-025-07515-7 |
| Effects of a cardiometabolic risk–reducing dietary pattern health education intervention on cardiometabolic disease risk in community-dwelling older adults in China: a cluster-randomized clinical trial | randomized trial | 2 | 2026-08-01 | 10.1016/j.jnha.2026.100902 |

## What The Sources Report

- The positive symptoms manifest as hallucinations, delusions, and disorganized speech or behavior, while the negative symptoms consist of cognitive impairment with reduced motivation and expressiveness factors that affect memory and mental processing. [Kassar Omar (2025); evidence level 1]
- Patients with schizophrenia have a mortality rate of 2-3-fold compared to healthy people, with a reduced expected life of 10-20 years. [Kassar Omar (2025); evidence level 1]
- Substantial evidence has supported the beneficial role of healthy dietary factors in preventing the occurrence and development of CMDs and atherosclerosis in the aging population. [Wu Qi (2026); evidence level 2]
- Therefore, we performed a 12-month cluster-randomized controlled intervention trial to evaluate the effects of the RCMDR dietary pattern on clustered cardiometabolic risk, common carotid artery (CCA) atherosclerosis parameters, CMD risk factors (blood lipids, blood glucose, insulin sensitivity, homocysteine (Hcy), blood pressure) and body composition in community-dwelling older adults. [Wu Qi (2026); evidence level 2]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For sulforaphane blood glucose randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Kassar Omar (2025). Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. DOI: 10.1186/s12888-025-07515-7. PMCID: PMC12581406. PMID: 41184790. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12581406/
- Wu Qi (2026). Effects of a cardiometabolic risk–reducing dietary pattern health education intervention on cardiometabolic disease risk in community-dwelling older adults in China: a cluster-randomized clinical trial. DOI: 10.1016/j.jnha.2026.100902. PMCID: PMC13273878. PMID: 42269349. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13273878/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.